The State reports: Roche raises price in hostile offer for Genentech

Hanging over the talk of Genentech's value has been upcoming study data on the blockbuster cancer drug Avastin's effectiveness in treating early-stage colon cancer. The drug is already approved for various types of breast, lung and colon cancers and is the company's best-selling product. If the latest study is successful, the share price will likely rise, several analysts have said, but the opposite could also hold true.